TALK vs CLOV vs CVS vs DOCS

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate CVS Health Corporation (CVS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 23. 5x versus Talkspace, Inc. at 129. 5x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.

0%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: CVS returned +3. 5% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 2312% more volatile than CVS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 53. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DOCS: 64. 4% to $42. 79.

In this comparison, CVS (3.

1% yield) pays a dividend. TALK, CLOV, DOCS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TALK is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock; DOCS is a small-cap high-growth stock. CVS pays a dividend while TALK, CLOV, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.